Enveric Biosciences (STU:SLZ) Operating Cash Flow per Share : €-9.88 (TTM As of Mar. 2025)

View and export this data going back to 2021. Start your Free Trial

What is Enveric Biosciences Operating Cash Flow per Share?

Enveric Biosciences's operating cash flow per share for the three months ended in Mar. 2025 was €-1.23. Enveric Biosciences's operating cash flow per share for the trailing twelve months (TTM) ended in Mar. 2025 was €-9.88.

During the past 3 years, the average Operating Cash Flow per Share Growth Rate was 65.40% per year. During the past 5 years, the average Operating Cash Flow per Share Growth Rate was 58.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the OCF Growth Rate using Operating Cash Flow per Share data.

The historical rank and industry rank for Enveric Biosciences's Operating Cash Flow per Share or its related term are showing as below:

STU:SLZ' s 3-Year OCF Growth Rate Range Over the Past 10 Years
Min: 41.4 Med: 52.9 Max: 65.4
Current: 65.4

During the past 13 years, Enveric Biosciences's highest 3-Year average Operating Cash Flow per Share Growth Rate was 65.40% per year. The lowest was 41.40% per year. And the median was 52.90% per year.

STU:SLZ's 3-Year OCF Growth Rate is ranked better than
94.08% of 1216 companies
in the Biotechnology industry
Industry Median: 9.1 vs STU:SLZ: 65.40

Enveric Biosciences Operating Cash Flow per Share Historical Data

The historical data trend for Enveric Biosciences's Operating Cash Flow per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Enveric Biosciences Operating Cash Flow per Share Chart

Enveric Biosciences Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Operating Cash Flow per Share

Get a 7-Day Free Trial

-399.63

-327.10

-168.62

-89.75

-14.67

Enveric Biosciences Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Operating Cash Flow per Share	Get a 7-Day Free Trial															-8.95	-5.30	-1.44	-1.91	-1.23

Competitive Comparison of Enveric Biosciences's Operating Cash Flow per Share

For the Biotechnology subindustry, Enveric Biosciences's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Enveric Biosciences's Price-to-Operating-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Enveric Biosciences's Price-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Enveric Biosciences's Price-to-Operating-Cash-Flow falls into.

Save Embed

;

Save Embed

;

Enveric Biosciences Operating Cash Flow per Share Calculation

Operating Cash Flow per Share is the amount of Cash Flow from Operations per outstanding share of the company's stock.

Enveric Biosciences's Operating Cash Flow per Share for the fiscal year that ended in Dec. 2024 is calculated as

Operating Cash Flow per Share (A: Dec. 2024 )	=	Cash Flow from Operations (A: Dec. 2024 )	/	Shares Outstanding (Diluted Average) (A: Dec. 2024 )
	=	-7.378	/	0.503
	=	-14.67

Enveric Biosciences's Operating Cash Flow per Share for the quarter that ended in Dec. 2024 is calculated as

Operating Cash Flow per Share (Q: Mar. 2025 )	=	Cash Flow from Operations (Q: Mar. 2025 )	/	Shares Outstanding (Diluted Average) (Q: Mar. 2025 )
	=	-2.213	/	1.798
	=	-1.23

Operating Cash Flow per Share for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €-9.88

Enveric Biosciences Operating Cash Flow per Share Related Terms

Thank you for viewing the detailed overview of Enveric Biosciences's Operating Cash Flow per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Enveric Biosciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Enveric Biosciences Inc (STU:SLZ) » Definitions » Operating Cash Flow per Share

Comparable Companies

Traded in Other Exchanges

ENVB:USA

Address

4851 Tamiami Trail N, Suite 200, Naples, FL, USA, 34103

Website

https://www.enveric.com

Enveric Biosciences Inc is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, addiction, and other psychiatric disorders. The company's program, EB-003, is a first-in-class approach to the treatment of difficult-to-address mental health disorders designed to promote neuroplasticity without inducing hallucinations in the patient. The company is also developing EB-002, formerly EB-373, a next-generation synthetic prodrug of the active metabolite, psilocin, which is being studied as a treatment for psychiatric disorders.